- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- inhaled mosliciguat, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Volunteer
- Interventions
- Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- Mosliciguat, Dry Powder Inhaler, Placebo
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more